Evidence map›Paper›PMID 33585233›Full record

ArticleFrontiers in oncology2020

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR.

Qiumei Yao, Yinlei Bai, Shaji Kumar, Elaine Au, Alberto Orfao, Chor Sang Chim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Identification and Analysis of the Expression of theInternational journal of molecular sciences · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiumei YaoDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
Yinlei BaiInstitute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Elaine AuDepartment of Pathology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
Alberto OrfaoDepartment of Medicine and Cytometry Service (Nucleus), Cancer Research Centre (IBMCC, USAL-CSIC) and CIBERONC, Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain.
Chor Sang ChimDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10

Indexed as

allele-specific oligonucleotide real-time quantitative-PCRminimal residual diseasemultiple myelomanext-generation sequencingsensitivity

Identifiers

PMID33585233
PMCPMC7878533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.